Synerkine Pharma B.V. focuses on development of novel fusion proteins, called Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.
| Website | https://synerkinepharma.com |
| Employees | 6 (4 on RocketReach) |
| Founded | 2018 |
| Industry | Biotechnology, Biotechnology Research, Science and Engineering, Drug Delivery, Health Care |
| Keywords | Therapeutic Proteins, Biotechnology, Pharmaceutical Development, Drug Development, Biologics, Protein Engineering, Immunology, Novel Therapeutics, Clinical Development, Preclinical Development, Biopharma, Drug Discovery, Molecular Biology, Pharmaceutical Research, Innovative Medicines, Health Technology |
| Competitors | Johnson & Johnson, Roche, Novartis, Pfizer, Sanofi, AstraZeneca, Regeneron, Gilead Sciences, Biogen, Moderna Therapeutics +42 more (view full list) |
Looking for a particular Synerkine Pharma employee's phone or email?
Synerkine Pharma Questions
Hans Preusting is the CEO of Synerkine Pharma.
4 people are employed at Synerkine Pharma.
Top Synerkine Pharma Employees
Related Companies
